Zobrazeno 1 - 10
of 157
pro vyhledávání: '"David M, Waterhouse"'
Autor:
David M. Waterhouse, Janet L. Espirito, Marc D. Chioda, Bismark Baidoo, Jack Mardekian, Nicholas J. Robert, Elizabeth T. Masters
Publikováno v:
Drugs - Real World Outcomes, Vol 7, Iss 4, Pp 261-269 (2020)
Abstract Background Data are sparse concerning the sequential use of multiple anaplastic lymphoma kinase (ALK) inhibitors for ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). Objective This study investigated sequencing
Externí odkaz:
https://doaj.org/article/03f7a6aab37f4777abb0d63f1f78689f
Autor:
Jonathan W. Goldman, David M. Waterhouse, Ben George, Peter J. O'Dwyer, Rafia Bhore, Sibabrata Banerjee, Larry Lyons, Chrystal U. Louis, Teng Jin Ong, Karen Kelly
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Introduction: Multicenter, phase I study of concurrent and delayed nivolumab plus nab-paclitaxel/carboplatin in advanced non-small cell lung cancer (NSCLC).Methods: Chemotherapy-naive patients with advanced NSCLC (ineligible for potentially curative
Externí odkaz:
https://doaj.org/article/36deb3212f774536b9f45353cdf8f360
Autor:
David M. Waterhouse, Patrick Ward, Suzzette Arnal, Marcus Neubauer, David R. Drosick, Dan Davies, Molly A. Mendenhall
Publikováno v:
JCO Oncology Practice.
PURPOSE Non–small-cell lung cancer (NSCLC), the leading cause of cancer death in the United States, accounts for 85% of all lung cancer cases. Biomarker testing is an integral part of the care of patients with NSCLC. Despite broad consensus recomme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aad7bda2be910d1e00886d26c9d3fbf7
https://doi.org/10.1200/op.22.00817
https://doi.org/10.1200/op.22.00817
Autor:
Julie Gralow, Melinda Kaltenbaugh, Charu Aggarwal, Daniel J Mesenhowski, Alicia L. Patrick, Richard L. Schilsky, Ronald C. Chen, Eric J. Clayton, Elizabeth Garrett-Mayer, Suanna S. Bruinooge, Kathryn Finch Mileham, Alexander I. Spira, David M. Waterhouse, Christiana Davis, Abdul Rahman Jazieh, Jen Hanley Williams, Susan G. Moore
Publikováno v:
JCO Oncology Practice. 18:e426-e441
PURPOSE:People with cancer are at increased risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. ASCO's COVID-19 registry promotes systematic data collection across US oncology practices.METHODS:Participating practices ent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4fcc59ecc0c7ac068f8d9400a8d6625
https://doi.org/10.1200/op.21.00394
https://doi.org/10.1200/op.21.00394
Autor:
Peter J. O'Dwyer, Teng Jin Ong, Chrystal U. Louis, Larry Lyons, Sibabrata Banerjee, Rafia Bhore, Daniel W. Pierce, David J. Reiss, Thomas Lila, Hatem H. Soliman, Daniel Ricardo Carrizosa, Rishi Jain, Aparna Parikh, Martin Guiterrez, David M. Waterhouse, E. Gabriela Chiorean, Aparna Kaylan, Ben George, Edward J. Kim, Howard S. Hochster, Zev A. Wainberg
Baseline (screening) vs treatment cycle 2 (P=.06; paired t test). For patient 5, baseline data were not available.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcd98b63eb49f579d01cbe44a0a85231
https://doi.org/10.1158/1078-0432.22475423
https://doi.org/10.1158/1078-0432.22475423
Autor:
Peter J. O'Dwyer, Teng Jin Ong, Chrystal U. Louis, Larry Lyons, Sibabrata Banerjee, Rafia Bhore, Daniel W. Pierce, David J. Reiss, Thomas Lila, Hatem H. Soliman, Daniel Ricardo Carrizosa, Rishi Jain, Aparna Parikh, Martin Guiterrez, David M. Waterhouse, E. Gabriela Chiorean, Aparna Kaylan, Ben George, Edward J. Kim, Howard S. Hochster, Zev A. Wainberg
Purpose:Assess safety and efficacy of nivolumab plus nab-paclitaxel and gemcitabine in patients with locally advanced/metastatic pancreatic cancer in a two-part, open-label, phase I trial.Patients and Methods:Fifty chemotherapy-naive patients receive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91944ff29f7b99aa8e56f618a1dd6950
https://doi.org/10.1158/1078-0432.c.6529076.v1
https://doi.org/10.1158/1078-0432.c.6529076.v1
Autor:
Peter J. O'Dwyer, Teng Jin Ong, Chrystal U. Louis, Larry Lyons, Sibabrata Banerjee, Rafia Bhore, Daniel W. Pierce, David J. Reiss, Thomas Lila, Hatem H. Soliman, Daniel Ricardo Carrizosa, Rishi Jain, Aparna Parikh, Martin Guiterrez, David M. Waterhouse, E. Gabriela Chiorean, Aparna Kaylan, Ben George, Edward J. Kim, Howard S. Hochster, Zev A. Wainberg
Percentage lymphocyte subset Ki67+. All patient visits are binned by treatment cycle. Data at baseline and treatment cycle 3 were compared using the Wilcoxon signed rank test. All available data are illustrated; however, statistical comparisons were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1af451ccc2b3f88d0ca2643cefe85947
https://doi.org/10.1158/1078-0432.22475429
https://doi.org/10.1158/1078-0432.22475429
Autor:
Peter J. O'Dwyer, Teng Jin Ong, Chrystal U. Louis, Larry Lyons, Sibabrata Banerjee, Rafia Bhore, Daniel W. Pierce, David J. Reiss, Thomas Lila, Hatem H. Soliman, Daniel Ricardo Carrizosa, Rishi Jain, Aparna Parikh, Martin Guiterrez, David M. Waterhouse, E. Gabriela Chiorean, Aparna Kaylan, Ben George, Edward J. Kim, Howard S. Hochster, Zev A. Wainberg
T-Cell Tumor Infiltration in Tissue-Matched Baseline (screening) and On-Treatment Metastatic Tumors (arm B parts 1 and 2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5462aa83ef7e3c2c1c1145183bef1b4
https://doi.org/10.1158/1078-0432.22475426
https://doi.org/10.1158/1078-0432.22475426
Autor:
Peter J. O'Dwyer, Teng Jin Ong, Chrystal U. Louis, Larry Lyons, Sibabrata Banerjee, Rafia Bhore, Daniel W. Pierce, David J. Reiss, Thomas Lila, Hatem H. Soliman, Daniel Ricardo Carrizosa, Rishi Jain, Aparna Parikh, Martin Guiterrez, David M. Waterhouse, E. Gabriela Chiorean, Aparna Kaylan, Ben George, Edward J. Kim, Howard S. Hochster, Zev A. Wainberg
Investigator-assessed PFS and OS in patients with PD-L1 expression cutoff of 1% (A, B) or 5% (C, D). HR, hazard ratio; mo, months; OS, overall survival; PD-L1, programmed cell death ligand-1; PFS, progression-free survival.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46e9db745e67db99e4742619e1ece12c
https://doi.org/10.1158/1078-0432.22475435.v1
https://doi.org/10.1158/1078-0432.22475435.v1
Autor:
Peter J. O'Dwyer, Teng Jin Ong, Chrystal U. Louis, Larry Lyons, Sibabrata Banerjee, Rafia Bhore, Daniel W. Pierce, David J. Reiss, Thomas Lila, Hatem H. Soliman, Daniel Ricardo Carrizosa, Rishi Jain, Aparna Parikh, Martin Guiterrez, David M. Waterhouse, E. Gabriela Chiorean, Aparna Kaylan, Ben George, Edward J. Kim, Howard S. Hochster, Zev A. Wainberg
Patients were enrolled in Arm B Part 1 after the safety oversight committee deemed Arm A Part 1 safe. DRC, data review committee; LAPC, locally advanced pancreatic cancer; MPC, metastatic pancreatic cancer; RP2D, recommended Part 2 dose.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::898ef1dea38981f86f8ebf1a7d51ab9a
https://doi.org/10.1158/1078-0432.22475438
https://doi.org/10.1158/1078-0432.22475438